Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial.
Autor: | Honarkar Shafie E; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran., Taheri F; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran., Alijani N; Department of Infectious Disease, Shariati Hospital, Tehran university of medical sciences, Tehran, Iran., Okhovvat AR; Central Herbarium, Tehran University, Tehran, Iran., Goudarzi R; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran., Borumandnia N; Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Aghaghazvini L; Department of Radiology, Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran., Rezayat SM; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran., Jamalimoghadamsiahkali S; Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran., Hosseinzadeh-Attar MJ; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. |
---|---|
Jazyk: | angličtina |
Zdroj: | Phytotherapy research : PTR [Phytother Res] 2022 Feb; Vol. 36 (2), pp. 1013-1022. Date of Electronic Publication: 2022 Jan 12. |
DOI: | 10.1002/ptr.7374 |
Abstrakt: | It has been more than a year since the outbreak of COVID-19, and it is still the most critical issue of the healthcare system. Discovering effective strategies to treat infected patients is necessary to decrease the mortality rate. This study aimed to determine the effects of nanocurcumin on the severity of symptoms and length of hospital stay (LOS) in COVID-19 patients. Forty-eight COVID-19 patients were randomly assigned into nanocurcumin (n = 24) and placebo (n = 24) groups receiving 160 mg/day nanocurcumin or placebo capsules for 6 days. Mean differences of O (© 2022 John Wiley & Sons Ltd.) |
Databáze: | MEDLINE |
Externí odkaz: |